Other Consolidated Financial Statement Detail

Supplemental Cash Flow Information

Supplemental disclosure of cash flow information for the years ended December 31, 2018, 2017 and 2016, is as follows:



	For the Years Ended December 31,
(In millions)	2018		2017		2016
Cash paid during the year for:
Interest	$	243.2	$	281.7	$	281.2
Income taxes	$	1,007.1	$	1,066.4	$	1,642.2

Non-cash Operating, Investing and Financing Activity

In the fourth quarter of 2018 we accrued $300.0 million upon reaching $20.0 billion in total cumulative sales of the Fumapharm Products, which will be paid in the first quarter of 2019. In the fourth quarter of 2017 we accrued $600.0 million upon reaching $15.0 billion and $16.0 billion in total cumulative sales of the Fumapharm Products, which was paid in the first quarter of 2018. These amounts, net of tax benefit, were accounted for as increases to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. For additional information on the contingent payments to the former shareholders of Fumapharm AG and holders of their rights, please read Note 22, Commitments and Contingencies, to these consolidated financial statements.

In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately $100.0 million and $150.0 million in our consolidated balance sheets as of December 31, 2018 and 2017, respectively. For additional information on the construction of our manufacturing facility in Solothurn, Switzerland, please read Note 11, Property, Plant and Equipment, to these consolidated financial statements.

In December 2016 we accrued $454.8 million related to the settlement and license agreement with Forward Pharma. For additional information on the settlement and license agreement with Forward Pharma, please read Note 7, Intangible Assets and Goodwill, to these consolidated financial statements.

Other Income (Expense), Net

Components of other income (expense), net, are summarized as follows:



	For the Years Ended December 31,
(In millions)	2018			2017			2016
Interest income	$	112.5		$	78.5		$	63.4
Interest expense	(200.6		)	(250.8		)	(260.0		)
Gain (loss) on investments, net	119.5			(36.3		)	6.0
Foreign exchange gains (losses), net	(9.9		)	6.3			(9.8		)
Other, net	(10.5		)	(14.7		)	(18.3		)
Total other income (expense), net	$	11.0		$	(217.0	)	$	(218.7	)

For the year ended December 31, 2018, gain (loss) on investments, net, as reflected in the table above, substantially relate to marketable equity securities held at December 31, 2018.

Other Current Assets

Other current assets were $687.6 million and $962.0 million as of December 31, 2018 and 2017, respectively, and include prepaid taxes totaling $271.2 million and $657.6 million, respectively.

Investments and other assets

Investments and other assets were $1,690.6 million as of December 31, 2018, including $680.6 million and $563.8 million related to our investments in Samsung Bioepis and Ionis, respectively. For additional information on our collaboration arrangements with Samsung Bioepis and Ionis, please read Note 19, Collaborative and Other Relationships, to these consolidated financial statements.

Accrued Expenses and Other

Accrued expenses and other consists of the following:



	As of December 31,
(In millions)	2018		2017
Revenue-related reserves for discounts and allowances	$	874.7	$	572.0
Current portion of contingent consideration obligations	444.8		844.6
Employee compensation and benefits	320.9		297.7
Royalties and licensing fees	224.7		206.7
Construction in progress	125.2		159.7
Collaboration expenses	261.6		183.7
Other	609.3		636.9
Total accrued expenses and other	$	2,861.2	$	2,901.3

Other Long-term Liabilities

Other long-term liabilities were $1,389.4 million and $1,628.7 million as of December 31, 2018 and 2017, respectively, and include accrued income taxes totaling $791.4 million and $979.8 million, respectively.